💨 Abstract

Axsome Therapeutics reported a Q2 loss of $48 million, or 97 cents per share, surpassing Wall Street estimates of $1 per share. Adjusted losses were 92 cents per share. The company's revenue was $150 million, exceeding expectations of $139.6 million. Axsome’s stock has risen 22% year-to-date and over the past year.

Courtesy: WTOP Staff